Overview

  • Product name

    Anti-Caldesmon/CDM antibody [E89] (HRP)
    See all Caldesmon/CDM primary antibodies
  • Description

    Rabbit monoclonal [E89] to Caldesmon/CDM (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    within Human Caldesmon/CDM aa 750 to the C-terminus. The exact sequence is proprietary. Synthetic phospho peptide corresponding to residues surrounding Ser789 of human Caldesmon. This antibody is NOT phospho-specific, however, and will recognize total endogenous protein.
    Database link: Q05682

  • Positive control

    • WB: HeLa and NIH3T3 cell lysates
  • General notes

     

     

     This product was previously labelled as Caldesmon

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab208234 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/15000. Detects a band of approximately 75 kDa (predicted molecular weight: 93 kDa).

Target

  • Function

    Actin- and myosin-binding protein implicated in the regulation of actomyosin interactions in smooth muscle and nonmuscle cells (could act as a bridge between myosin and actin filaments). Stimulates actin binding of tropomyosin which increases the stabilization of actin filament structure. In muscle tissues, inhibits the actomyosin ATPase by binding to F-actin. This inhibition is attenuated by calcium-calmodulin and is potentiated by tropomyosin. Interacts with actin, myosin, two molecules of tropomyosin and with calmodulin. Also play an essential role during cellular mitosis and receptor capping.
  • Tissue specificity

    High-molecular-weight caldesmon (isoform 1) is predominantly expressed in smooth muscles, whereas low-molecular-weight caldesmon (isoforms 2, 3, 4 and 5) are widely distributed in non-muscle tissues and cells. Not expressed in skeletal muscle or heart.
  • Sequence similarities

    Belongs to the caldesmon family.
  • Domain

    The N-terminal part seems to be a myosin/calmodulin-binding domain, and the C-terminal a tropomyosin/actin/calmodulin-binding domain. These two domains are separated by a central helical region in the smooth-muscle form.
  • Post-translational
    modifications

    In non-muscle cells, phosphorylation by CDK1 during mitosis causes caldesmon to dissociate from microfilaments. Phosphorylation reduces caldesmon binding to actin, myosin, and calmodulin as well as its inhibition of actomyosin ATPase activity. Phosphorylation also occurs in both quiescent and dividing smooth muscle cells with similar effects on the interaction with actin and calmodulin and on microfilaments reorganization.
  • Cellular localization

    Cytoplasm > cytoskeleton. Cytoplasm > myofibril. On thin filaments in smooth muscle and on stress fibers in fibroblasts (nonmuscle).
  • Information by UniProt
  • Database links

  • Alternative names

    • CAD antibody
    • CALD 1 antibody
    • CALD1 antibody
    • CALD1_HUMAN antibody
    • Caldesmon 1 antibody
    • Caldesmon 1 Isoform 1 antibody
    • Caldesmon 1 Isoform 2 antibody
    • Caldesmon 1 Isoform 3 antibody
    • Caldesmon 1 Isoform 4 antibody
    • Caldesmon 1 Isoform 5 antibody
    • Caldesmon antibody
    • Caldesmon1 antibody
    • CDM antibody
    • H CAD antibody
    • HCAD antibody
    • L CAD antibody
    • LCAD antibody
    • MGC21352 antibody
    • NAG22 antibody
    see all

Images

  • All lanes : Anti-Caldesmon/CDM antibody [E89] (HRP) (ab208234) at 1/5000 dilution

    Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : NIH 3T3 (Mouse) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 93 kDa
    Observed band size: 75 kDa
    why is the actual band size different from the predicted?


    Exposure time: 4 minutes


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab208234 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab208234 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab208234.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up